Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Hodgkin Disease 33Lymphoma 17Lymphoma, Large-Cell, Anaplastic 15Hematologic Diseases 13Lymphoma, Non-Hodgkin 10Recurrence 9Lymphoma, T-Cell 7Lymphoma, T-Cell, Peripheral 6Lymphoma, Large B-Cell, Diffuse 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphatic Diseases 3Leukemia 3Immunoblastic Lymphadenopathy 3Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Histologic Type 2Lymphoproliferative Disorders 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myeloid, Acute 2Immunoproliferative Disorders 2Immune System Diseases 2Enteropathy-Associated T-Cell Lymphoma 2Waldenstrom Macroglobulinemia 1Testicular Neoplasms 1Nonseminomatous germ cell tumor 1

Interventions

midostaurin 2sarilumab 1obatoclax 1nilotinib 1ibrutinib 1avapritinib 1Everolimus 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mastocytosis, Systemic × Brentuximab Vedotin × Clear all
NCT01807598 2019-01-29

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Stanford University

Phase 2 Completed
10 enrolled 14 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡